SWTX - SpringWorks Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

SpringWorks Therapeutics, Inc.

100 Washington Boulevard
Stamford, CT 06902
United States

SectorConsumer Goods
IndustryRubber & Plastics
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Saqib IslamCEO & Director586.51kN/A1970
Dr. Jens Renstrup M.B.A., M.D.Chief Medical Officer440.65kN/A1965
Dr. Badreddin Edris Ph.D.Chief Bus. Officer435.71kN/A1987
Dr. Stephen P. SquintoActing Head of R&D and Director100kN/A1956
Mr. Francis I. Perier Jr.Chief Financial OfficerN/AN/A1960
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its advanced product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; and Nirogacestat + belantamab mafodotin, which is in Phase 1b clinical trials for the treatment of relapsed or refractory multiple myeloma. In addition, it is developing Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trials in patients with advanced or refractory solid tumors; and BGB-3245, an investigational oral selective small molecule inhibitor of specific BRAF driver mutations and genetic fusions, which is in preclinical studies in a range of tumor models with BRAF mutations or fusions. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline plc to develop combination approaches with nirogacestat and mirdametinib, as well as other standalone medicines. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

Corporate Governance

SpringWorks Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.